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Trypanosoma cruzi infection causes Chagas disease, which affects 7 million people
worldwide. Two drugs are available to treat it: benznidazole and nifurtimox. Although
both are efficacious against the acute stage of the disease, this is usually asymptomatic
and goes undiagnosed and untreated. Diagnosis is achieved at the chronic stage, when
life-threatening heart and/or gut tissue disruptions occur in ∼30% of those chronically
infected. By then, the drugs’ efficacy is reduced, but not their associated high toxicity.
Given current deficiencies in diagnosis and treatment, a vaccine to prevent infection
and/or the development of symptoms would be a breakthrough in the management
of the disease. Current vaccine candidates are mostly based on the delivery of single
antigens or a few different antigens. Nevertheless, due to the high biological complexity
of the parasite, targeting as many antigens as possible would be desirable. In this
regard, an epitope-based vaccine design could be a well-suited approach. With this
aim, we have gone through publicly available databases to identify T. cruzi epitopes
from several antigens. By means of a computer-aided strategy, we have prioritized a
set of epitopes based on sequence conservation criteria, projected population coverage
of Latin American population, and biological features of their antigens of origin. Fruit of
this analysis, we provide a selection of CD8+ T cell, CD4+ T cell, and B cell epitopes that
have <70% identity to human or human microbiome protein sequences and represent
the basis toward the development of an epitope-based vaccine against T. cruzi.
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INTRODUCTION
Chagas disease is a devastating neglected disease that affects several million people worldwide (1).
It is caused by the protozoan parasite Trypanosoma cruzi (T. cruzi; order: Kinetoplastida; family
Trypanosomatidae). The parasite is transmitted by triatomine insect vectors (order Hemiptera;
family Reduviidae) endemic to the Americas, and through vector-independent routes such as blood
transfusion or mother-to-child (1). The latter are of relevance in endemic and non-endemic regions
alike where the disease has been globalized in recent decades due to population movements (2).
There are two drugs to treat the infection: benznidazole (BNZ) and nifurtimox (NFX). Although
highly efficacious against the short (8–12 weeks long) acute stage of the disease, this stage is mostly
Michel-Todó et al. Epitope-Based Vaccine Ensemble for Chagas Disease
asymptomatic and therefore it generally goes undiagnosed and
untreated. It is at the chronic stage, which can last from years
to decades, when the onset of symptoms occurs. It is usually
then when the infection is diagnosed and treatment is provided,
but unfortunately, the drugs’ efficacy at this stage is reduced
(1). Moreover, BNZ and NFX long dosage regimes have severe
toxicity associated, which can lead to treatment discontinuation
and failure (3, 4). Without treatment or upon its failure, about
30% of the chronically infected people will suffer incapacitating
heart and/or gut tissue disruptions that can be life-threatening
(1). If the damage to the tissues is advanced, diagnosis and
treatment might arrive too late to reverse the situation (5).
In view of present deficiencies to get access to diagnosis and
treatment, a Chagas disease vaccine that could either prevent
the infection or the development of the symptomatology would
mean a major breakthrough in the management of the disease.
Two parasitic forms co-exist in T. cruzi-infected humans:
amastigotes replicate intracellularly in multiple host cell types
and transform into circulating motile trypomastigotes that
spread the infection upon bursting the host cells. The existence
of these two forms in the intracellular and extracellular domains
requires a broad, complete, active, and robust parasite-specific
immune response to control the infection. Despite the immune
system’s intervention, some parasites manage to escape and, at
a simple conceptual level, this is how the parasite persists (6).
Recently, parasite dormancy has also been described as another
mechanism of immune evasion (7). The aim of a vaccine for
Chagas disease will be to induce a specific and protective immune
memory against the parasite able to control the infection and halt
the tissue damage driven by the parasite.
Experimental animal models and studies with clinical samples
have shown that cellular immunity mediated by antigens specific
for CD8+ T cells are essential to control the infection (8).
Activated CD4+ T cells are critical for the secondary expansion
of CD8+ cytotoxic T cells and their efficient cytotoxic activity.
Moreover, the relevance of CD4+ T cell-mediated immunity
during T. cruzi infection was demonstrated when deletion of
this cell population in infected mice resulted in increased
parasitemia and exacerbation of pathology (9), as well as
considering that in Chagas disease patients co-infected with
HIV, a decrease in the amount of CD4+ T cells correlates with
increased parasitic loads (10). Besides, parasite-specific B cell
responses have been reported as fundamental to keep a systemic
anti-parasitic response and prevent exhaustion of parasite-
specific CD8+ T cells (11), plus parasite-specific antibodies are
crucial to halt the infection of new cells by free-swimming
trypomastigotes (12).
Several vaccine candidates against T. cruzi infection have
been tested in the last decades (13). The majority of them
were based on the delivery of single antigens or fragments
of single antigens either as recombinant protein subunits or
vectored by recombinant viruses or bacteria (13). In addition,
other approaches have relied on chimeric protein constructions
as immunogens (14, 15). The most advanced candidates have
reached evaluation in dog (16, 17) and non-human primate
(18) models of T. cruzi infection or have been shown to ex
vivo recall memory responses in chronic Chagasic patients from
Mexico (19), but none has already gone beyond preclinical
developmental stages.
Two parasite-related issues greatly hamper vaccine
development for Chagas disease: the wide phenotypic diversity
of the parasite, and its high biological complexity. T. cruzi strains
infecting humans are classified in six different genotypes or
Discrete Typing Units (20) and can commonly cause mixed
infections (21, 22). Moreover, each parasite strain has more than
10,000 protein coding genes (CDS) per haploid genome (23).
Thus, the first step of the vaccine development process, i.e., the
selection of the desired antigens that will be used as immunogens,
is a hard-to-navigate crossroads. Aimed at increasing the chances
of progression into clinical testing, we have devised a strategy that
might enable overcoming this inconvenience. It is based on an
epitope-based vaccine design that would allow the delivery and
evaluation of multiple T. cruzi epitopes from multiple parasitic
antigens in one single construct. Building on an emerging
paradigm of rational epitope-based vaccine design (24), we have
applied tailor-made and publicly available immunoinformatics
resources to make a selection of parasite-specific CD8+ T cell,
CD4+ T cell, and B cell epitopes, prioritized accordingly to
sequence conservation criteria, projected protection coverage
(PPC) in populations of Latin America, and lack of identity
to human genome and human microbiome proteins. Similarly
to other studies (25–28), all the epitopes selected were either
validated or predicted in the human immunological context.
Such strategy could be useful toward the design and further
development of vaccine candidates against complex pathogens.
In this case, in an attempt to anticipate an epitope-based T. cruzi
vaccine ensemble, we provide a set of 18 CD8+ T cell epitopes
with >85% PPC in Latin America, 2 CD4+ T cell epitopes with
>99% coverage in Latin American populations, and 10 B cell
epitopes from exposed antigens.
MATERIALS AND METHODS
Collection of T. cruzi-Specific Epitopes
T and B cell epitope sequences were downloaded from the
Immune Epitope DataBase and Analysis Resource (IEDB; URL:
http://www.iedb.org/) (29). We retrieved T. cruzi (“antigen ID
5693”) epitopes from positive assays, which had been elicited in
the course of Chagas disease (“infectious disease”) in humans.
Major histocompatibility complex (MHC) Class I (CD8+ T cell
epitopes), MHC Class II (CD4+ T cell epitopes), and B cell
epitopes were collected separately. Information on their antigens
of origin was obtained too. We only considered CD8+ T cell
epitopes with nine residues as the majority of known epitopes
processed by MHC I are 9-mers (30). Any non-peptidic and/or
duplicate sequences were discarded from further analysis.
Collection of T. cruzi Protein Sequences
We downloaded all available T. cruzi protein sequences in
their Open Reading Frame format (ORF_AA) from the eight
parasite strains in TriTrypDB resource release 35 (31). These
are (DTU provided in parenthesis): CLBrener Non-Esmeraldo-
like (TcVI), CLBrener Esmeraldo-like (TcII), CLBrener (TcVI),
Dm28c (TcI), Esmeraldo (TcII), JRcl4 (TcI), SylvioX10 (TcI), and
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Tulacl2 (TcVI). A single file containing all the sequences (∼1 ×
107 ORF_AA FASTA entries) was generated. We excluded the
bat isolated Marinkellei strain due to its phylogenetic distance
to the others (32). Rationale for the data download as ORF_AA
is that we wanted to include all T. cruzi strains available in
TriTrypDB release 35, including JRcl4 and Tulacl2 strains, which
lack annotation details.
Generation of Clusters and Multiple
Sequence Alignments of T. cruzi Protein
Sequences
We used CD-HIT, running stand-alone with default settings,
to reduce the redundancy of T. cruzi proteins clustering them
with a shared identity >90% (33). The resulting ∼1.36 × 106
clusters were filtered down by means of custom scripts to retain
only those that contained protein sequences from at least seven
different strains. This way, we ensured that clusters considered
for further analysis represented the protein diversity among
almost all strains available. Protein sequences within each of the
remaining 13,571 clusters were aligned using MUSCLE (software
version 3.8.31) (34) to obtain an equivalent number of multiple
sequence alignments (MSA) with their corresponding consensus
sequences. Instead of the consensus sequence, built with pieces
from different sequences and thus unreal, we kept as reference of
each MSA the sequence in the alignment that was most similar to
the consensus one.
Generation of T. cruzi Invariable Proteome
and Identification of Conserved IEDB
Epitopes
The Shannon entropy (H) parameter (35) was used to measure
sequence variability on every position of the MSA according to




Pi log2 (Pi), (1)
where Piis the frequency of an amino acid of type i, and M
is the number of total different amino acids (20). H = 0 is
equivalent to no variation in a given position among the studied
protein sequences within the alignment, whereas higher values
correspond to higher variation in that position (36). Gaps were
considered as data. Those residues at positions with an entropy
value of H > 0.5 or H > 1.0 were masked in the assigned protein
reference sequence, substituting the residue symbol by an asterisk
symbol (∗). As a result, we obtained two masked FASTA files
(one for each entropy threshold) that represented the conserved
proteome of T. cruzi at those two levels of entropy.
Prediction of T Cell Epitopes
For de novo prediction of CD8+ T cell epitopes (peptides),
we used IEDB MHC I binding prediction algorithms
(http://tools.iedb.org/mhci) on the H > 0.5 T. cruzi-
masked proteome. Namely, these were ANN, NetMHCpan,
NetMHCstabpan (all based on artificial neural networks) (37–
39), CombLib_Sidney2008 (based on combinatorial peptide
libraries) (40), PickPocket (based on the analysis of the MHC
variable pocket residues) (41), SMM (stabilized matrix method)
(42), and SMMPMBEC (a Bayesian extension of the former)
(43). All methods were downloaded from IEDB and ran as
stand-alone programs. We considered for further analysis just
the 0.1% top scoring predicted epitopes from each tool that had
been predicted by five or more different methods and submitted
them to IEDB T cell Class I Immunogenicity predictor (http://
tools.iedb.org/immunogenicity/) (44).
For the prediction of CD4+ T cell epitopes (peptides), we used
the IEDB recommended method at MHC II binding predictions
tool (http://tools.iedb.org/mhcii/) (45, 46). CD4+ T cell epitopes
were predicted on the T. cruzi-masked proteome file (H > 0.5).
We considered for further analysis only the 0.01% top scoring
epitopes that were predicted to bind more than two human
leukocyte antigen (HLA) alleles.
Prediction of B Cell Epitopes
We followed two procedures for the prediction of B cell linear
epitopes: (1) a structure-based prediction on surface antigens
that contained at least one experimentally validated B cell
epitope from IEDB, and (2) the B cell epitopes prediction tool
BepiPred2.0 (47).
For (1), we elaborated a list with all the protein sequences
that contained an experimentally validated epitope from IEDB
and had been predicted to be surface exposed in the parasite.
The list was blasted to the Protein Data Bank (PDB) database
with BLASTP. Only one protein, the kinetoplastid membrane
protein-11 (KMP11), had a positive hit that covered >80% of the
queried sequence length. This was a KMP11 ortholog from the
closely related Trypanosoma brucei brucei (PDB accession 5Y70)
(48). Taking it as reference, we modeled the T. cruzi KMP11
onto it using MODELER (49). Then, we used the KMP11 model
to perform relative solvent accessibility (RSA) calculations with
NACCESS (50). Residues with RSA > 50% were considered as
good candidates for being part of a potential epitope. We used
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, to
visualize this B cell epitope on its modeled 3D structure.
For (2), we obtained at TriTrypDB a list of T. cruzi Esmeraldo-
like proteins predicted to be surface exposed, either because
they had a secretion signal peptide, or/and at least one trans-
membrane domain, or/and a glycosylphosphatidylinositol (GPI)
anchor signal. We manually curated the list taking into account
annotation details to retain those proteins that were highly likely
exposed, and we tagged them as “-exposed.” We fused them to
the file containing all T. cruzi ORF_AA sequences to generate
a file that included the “-exposed” tagged sequences as well.
Again, we clustered all these sequences using CD-HIT with
a shared identity threshold >90%, but this time, we kept for
further analysis only those clusters with at least eight different
strains that contained a “-exposed” tagged sequence. We then
followed the steps outlined in sections Generation of Clusters and
Multiple Sequence Alignments of T. cruzi Protein Sequences and
Generation of T. cruzi Invariable Proteome and Identification of
Conserved IEDB Epitopes to generate a masked (H > 0.5) T.
cruzi-invariant “exposed” file. We identified the invariant regions
of at least 15 residues long in it and created a FASTA file with the
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sequences of their corresponding antigens of origin. BepiPred2.0
was run on this file with a threshold set at >0.6 (47). We finally
crossed the results of this prediction with the conservation results
obtained from the previous procedure. Only those regions of
at least 15 residues long that were predicted as epitopes by
Bepipred2.0 and conserved accordingly to our analysis were
considered as putative epitopes for subsequent prioritization.
Prediction of T Cell Epitope HLA Binding
Profiles and Computation of Their
Projected Protection Coverage (PPC)
IEDB MHC I (38, 40, 42, 51) and MHC II (45, 46) binding
predictors were used to calculate the binding profiles of CD8+
T cell and CD4+ T cell epitopes, respectively. We used the IEDB-
recommended set of tools in both cases and a specific set of HLA
I alleles with more alleles in it so as to better represent Latin
American haplotypes (52) (Supplementary File 1) and the HLA
II reference set provided by IEDB, respectively. In agreement
with IEDB instructions, for MHC I epitopes, we kept for further
analysis those predicted epitopes within a top percentile rank ≤
1%. With respect to MHC II epitopes, we kept only those within
the top 3% percentile rank.
We calculated the epitopes PPC with IEDB Population
Coverage tool (http://tools.iedb.org/population/). PPCs of CD8+
T cell and CD4+ T cell epitopes for populations in Latin America
was queried by “area—country—ethnicity,” selecting Mexico and
South America (http://tools.iedb.org/population/). Throughout
the paper, PPC is expressed as an average of the PPC computed
for those two regions.We did not include Central America region
in the calculation because it provided scarce information from
very specific populations.
Antigens Annotation, Blast Searches, and
Other Analysis Procedures
We obtained the annotation data and biological features from
the antigens of origin of the conserved putative epitopes at
NCBI, UniProtKB, and TriTrypDB (31) in a sequential manner.
First, we blasted the antigens’ ORF_AA sequences (BLASTP at
NCBI) to get their NCBI GeneInfo (GI) identifier and Accession
numbers. We used the latter to query UniProtKB and retrieve
the available information, including antigens’ genes names at the
best annotated CLBrener Esmeraldo-like strain. With those, we
checked TriTrypDB Gene Page for further information retrieval
(e.g., transcriptomics and proteomics experimental data).
In order to find out the epitopes’ identity (% Id over queried
sequence length) to proteins in humans, we blasted them against
human microbiome protein sequences obtained from the NIH
Human Microbiome Project (53) and against the NCBI non
redundant (nr-) collection of human proteins. BLASTP was used
with default parameters except for PAM30 ScoringMatrix and an
expectation value (E-value) of 10,000.
We used SignalP, TargetP, and TMHMM (54) to predict
patterns compatible with surface-exposed molecules on proteins
with B cell epitopes. The possible presence of GPI-anchor signals
in these was predicted at PredGPI website (55).
Proteasome processing of the proposed ensemble was
predicted with NetChop using C-term 3.0 method and a
threshold set at 0.7 (56). We used VaxiJen v2.0 to analyze the
ensemble antigenicity (threshold at 0.5) (57), whereas its 3D
structure was modeled with RaptorX web portal (58). Raptor X
output also includes solvent accessibility (Acc) classification of
residues as buried (B), medium (M), or exposed (E) (58). PyMOL
Molecular Graphics System, Version 1.8 Schrödinger, was used
to visualize the ensemble 3D structure.
RESULTS
Identification of T. cruzi Conserved
Experimentally Validated Epitopes at IEDB
We obtained 125 unique T cell epitopes (114 CD8+ T cell and
11 CD4+ T cell epitopes) and 2000 unique B cell epitopes.
They are respectively listed in Tables S1A–C. The three lists of
experimentally verified epitopes were crossed with the masked
T. cruzi invariant proteome file with a threshold H > 1.
Only the epitopes that perfectly matched invariant regions were
considered hits. This way, we found three conserved CD8+ T
cell epitopes (Table 1) and 104 conserved B cell epitopes (see
Table S2). None of the 11 T. cruzi CD4+ T cell epitopes at IEDB
was found to be conserved.
The three conserved CD8+ T cell epitopes were from
two annotated antigens: major paraflagellar rod protein and
paraflagellar rod component (Table 1). Their predicted binding
profiles to HLA I were obtained and used to calculate their PPC.
The epitope with the highest individual PPC was GVSGVINAL
with 28.5% coverage; and the PPC of the combination of the
TABLE 1 | Conserved T. cruzi-specific CD8+ T cell epitopes from IEDB.
Epitope Antigen
namea
Antigen IDa Predicted HLA I profileb PPC%c Human hit (Id %)d Human microbiome hit (Id %)d
GVSGVINAL Paraflagellar rod component AAC32021.1 A*02:05, C*01:02, C*03:04 28.5 SJM29146.1 (77.8) KWZ91528.1 (77.8)
VPEVTDVTL Major paraflagellar rod protein AAA30221.1 B*51:02, C*01:02 8.9 NP_001254479.2 (77.8) EHM52480.1 (77.8)
KLEKIEDEL Major paraflagellar rod protein AAA30221.1 A*02:02, A*02:07 1.4 XP_016860742.1 (77.8) EGN34163.1 (77.8)
aAntigen name and ID number at NCBI database. bPredicted HLA I binding profile obtained at IEDB (http://tools.iedb.org/mhci). cAverage PPC for populations from Latin American
origin obtained at http://tools.iedb.org/population/ as described in Materials and Methods. dBlast hits in the NCBI human non-redundant protein collection and the Human Microbiome
Project database are identified by their Accession reference number at NCBI; the percentage of identity (%Id, number of identical residues per queried length) of each epitope to its
corresponding hit is shown in parenthesis.
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three epitopes was 30.6%. This imposed the identification ofmore
epitopes in order to achieve higher coverages. The need to search
for other CD8+ T cell epitopes was further confirmed due to the
>70% identity to human or human microbiome proteins of the
three sequences (Table 1).
Regarding B cell epitopes, the majority of the hits were from
non-exposed intracellular antigens (Table S2). However, B cell
epitopes lead to the production of an antibody response, which
is generally targeted against surface-exposed antigenic moieties.
Thus, we restricted the selection of conserved B cell epitopes
to those that originated from antigens predicted to be exposed,
reducing the list to 5 epitopes from two antigens (Table 2).
Four of the epitopes were from a lipophosphoglycan biosynthetic
protein [within heat shock protein (HSP) 90 family], and the
fifth was from the HSP70 T. cruzi protein. Since the large
majority of IEDB T. cruzi B cell epitopes had been discovered
by overlapping peptide arrays (59), the four epitopes at HSP90
antigen overlapped and were therefore fused into a single peptide
sequence (Table 2). A transmembrane region spanning from
positions 12 to 34 was predicted at the HSP90 antigen with
TMHMM v2.0 (54), but the fused peptide within it locates to
the outer exposed C-term of the molecule. No transmembrane
regions were predicted in HSP70. Nonetheless, HSP70 epitope
blasted with a very high identity to human genome and human
microbiome proteins and we had to discard it from further
consideration (Table 2). Thus, out of this “IEDB× INVARIANT
PROTEOME” approach, we were just able to identify a single
B cell epitope (GTDEGLLLPVDNDGDESS), which was unique
and conserved, and had <70% identity to any protein sequence
present in humans.
Prediction of T Cell Epitopes
T cells recognize epitopes when these are presented to them
bound to MHC molecules. Therefore, epitopes can be predicted
by computing their MHC-binding profile. Because of the
differences in the molecular interactions between epitopes and
MHC I and II complexes, the prediction of epitopes binding to
MHC I is more accurate than to MHC II (60). For both types, we
used IEDB tools as detailed in Materials and Methods.
We identified 127 predicted CD8+ T cell epitopes that were
unique and originated from almost as many different T. cruzi
conserved protein regions in the T. cruzi H > 0.5 masked
proteome. In order to further cure this list, all sequences were
submitted to the IEDB Class I Immunogenicity predictor (44),
which rendered 89 epitopes with a immunogenicity scoring >0.0
(Table S3A). Subsequently, we blasted them against the non-
redundant human protein collection and against the Human
Microbiome Project collection of protein sequences. Only 18 out
of those 89 peptides had identities<70% to any human or human
microbiome hit and were considered for further analysis, which
involved calculating their PPC (61) (Table 3). Individually, all
of them had a PPC > 10%, whereas altogether, they provided
a PPC of 88.3%. These 18 epitopes originated from as many as
17 different antigens with predominance of hypothetical proteins
(13 out of 17; Table 3). The remaining four annotated antigens
in the list were a phophoglycerate mutase, a putative DNA
repair protein, a chaperonin HSP60, and a phosphatase-like
protein (Table 3).
For the prediction of CD4+ T cell epitopes, we provided the
T. cruzi-masked (H > 0.5) proteome file to the IEDB MHC
II Binding Predictor (45, 46). In total, 2,497 potential epitopes
reported to bind from four to one distinct HLA II allele were
retrieved. We kept for further analysis the 17 T. cruzi-specific
CD4+ T cell peptides predicted to bind at least three distinct
HLAs, which also had identities to proteins in humans below
the 70% threshold (Table S3B). We then subjected them to
PPC computation and ultimately selected two CD4+ T cell
epitopes that individually provided 99.5 and 38.4% PPC, whose
combination was shown to project 99.8% coverage (Table 4).
Prediction of B Cell Epitopes
We focused on linear B cell epitopes because they can be
delivered isolated from their antigen context to induce selective
humoral responses. We applied two methods to predict B
cell epitopes: a structure-based approach and a sequence-based
approach with the tool Bepipred2.0 (47). With the former, we
identified a potential B cell epitope in the parasite KMP11 protein
(Figure 1A), an antigen that has been thoroughly researched
(63, 64). We identified a region of 15 residues long with all but
one fulfilling the RSA threshold (RSA > 50%). Visualization
of this region in the T. cruzi KMP11 3D model illustrates its
accessibility as the peptide clearly points away from the rest of
the molecule (Figure 1B). The epitope was shown to have <70%
identity to proteins in humans (Table 5), and an alignment of all
TABLE 2 | Conserved T. cruzi-specific B cell epitopes at IEDB from antigens predicted to be exposed.
Epitopea Antigen nameb Antigen IDb Antigen subcellular
localizationc






Q4DW89 S (2) XP_024308866 (66.7%) EHN62501.1 (44.4%) Y/Y
ATNGDTHLGGEDFDN Heat shock 70 kDa protein P05456 S (1) AAI12964.1 (93.0%) EEX50322.1 (100%) N/A
aThe underlined sequence is shared by four epitopes whose fusion yields this 18-amino-acid-long peptide. bAntigen name and antigen ID were obtained from UniProtKB database.
cSubcellular localization of antigens was predicted with TargetP1.1 (54). S, secreted; the number in brackets stands for TargetP prediction “Reliability class” (RC), which ranges from 1 to
5, where 1 indicates the strongest prediction. dBlast hits in the NCBI human non-redundant protein collection and Human Microbiome Project database are identified by their Accession
reference number at NCBI; the percentage of identity (% Id, number of identical residues per queried length) of each epitope to its corresponding hit is shown in parenthesis. eEvidence
of expression in mammalian infective stages: existence (Y) or not (N) of evidence of expression by transcriptomics and/or proteomics as described in TriTrypDB search by Gene ID (31).
N/A, not applicable since Hsp70 epitopes were not selected due to their high percentage of identity to protein sequences present in humans.
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TABLE 3 | Selection of predicted T. cruzi-specific CD8+ T cell epitopes.
Epitope Antigen namea Antigen IDa PPC (%)b Human hit (Id %) Microbiome hitc Evidence of exp.d
VYGRFYYRF Phosphoglycerate mutase XP_807293.1 52.5 NP_001316055.1 (55.6) ETN46456.1 Y/Y
RFFPSVFWR Hypothetical protein XP_811816.1 46.2 EAW98638.1 (66.7) EFR45113.1 Y/N
FPFCWLPTY Hypothetical protein XP_806973.1 39.1 NP_005305.1 (66.7) ETN41230.1 Y/N
MPAFQGWAF Hypothetical protein C3747_101g9 PWV07436.1 36.0 SJM35294.1 (66.7) ERS97746.1 Y/N
KICHVVFFR Hypothetical protein XP_807600.1 34.7 NP_060595.3 (66.7) EEG88082.1 Y*/Y
RTYHMIWNR Hypothetical protein C3747_25g140 PWV16110.1 34.7 AIE56486.1 (55.6) EGG52539.1 Y/N
RVFFWKVQR Putative SNF2 DNA repair protein PWV13412.1 34.7 AAN08628.1 (55.6) EPH21217.1 Y/N
MTFVFEARR Hypothetical protein XP_817046.1 31.3 NP_653173.1 (66.7) EFK35250.1 Y/N
KMWQRTFTR Chaperonin HSP60, mitochondrial precursor PWV11883.1 19.2 CCQ43203.1 (66.7) EGJ45866.1 –
RLWRWRCMR Hypothetical protein C3747_25g140 PWV16110.1 19.2 XP_011528872.1 (66.7) EKY00389.1 Y/N
RINFCFYVR Phosphatase-like protein XP_809619.1 19.1 NP_001275914.1 (55.6) EGF09027.1 Y/Y
RQRAILMYR Hypothetical protein C3747_84g29 PWV08907.1 18.2 XP_005256351.1 (66.7) EFV17694.1 Y/N
KMRVWRHQR Hypothetical protein XP_811814.1 15.3 XP_006723890.1 (66.7) EGC78513.1 Y/N
RMNLITWHR Hypothetical protein TCDM_03859 ESS67427.1 15.3 5WC2 (66.7) EFC97415.1 Y/Y
FHDQTIFCL Hypothetical protein XP_805332.1 15.2 BAG10460.1 (55.6) EUB31300.1 Y/N
MHDHYCFVL Leucine carboxyl methyltransferase XP_811822.1 15.2 NP_620154.2 (66.7) KGF29870.1 Y*/Y
IPMRRRRSL Hypothetical protein XP_818330.1 15.0 NP_579877.1 (66.7) EKU83050.1 Y/Y
FHFCITFCL Hypothetical protein XP_807567.1 11.3 EAW88842.1 (66.7) EEG29914.1 Y/N
aAntigen name and ID accession number at NCBI database. bPPC for Latin America calculated at IEDB Population Coverage tool (61). cPercentage of identity of all microbiome hits
blasted was 66.7%. dEvidence of expression in mammalian infective stages: existence (Y) or not (N) of evidence of expression by transcriptomics and/or proteomics as described in
TriTrypDB search by Gene ID (31); *the transcript expression value was higher in epimastigotes than in mammalian infective stages as described by Minning et al. (62).
TABLE 4 | Selection of predicted T. cruzi-specific CD4+ T cell epitopes.
Epitope Antigen namea Antigen IDa PPC (%)b Human hit (Id %)c Microbiome hit (Id %)c Evidence of exp.d
DDELFHYFLWTFFFIDLLYAVM Hypothetical protein XP_816368.1 95.9 BAC87213.1 (52.3) ERH31153.1 (43.91) Y/N
YIFIECFQIMRAFRLRGASFF Co-chaperone GrpE XP_804093.1 38.4 SJM30315.1 (28.6) EJN84302.1 (47.6) Y*/Y
aAntigen name and ID number at NCBI. bPPC for Latin America calculated at IEDB Population Coverage tool (61). cPercentage of identity is given in parenthesis and stands for the
number of identical residues per queried length of each epitope to its corresponding blasted hit. dEvidence of expression in mammalian infective stages: existence (Y) or not (N) of
evidence of expression by transcriptomics and/or proteomics as described in TriTrypDB search by Gene ID (31); *the transcript expression value was higher in epimastigotes than in
mammalian infective stages as described by Minning et al. (62).
the homologous sequences in the file containing all ORFs_AA
used in the study indicated that it was highly conserved in seven
out of the eight T. cruzi strains from TriTryDB release 35 used in
the study (Supplementary File 2).
The Bepipred2.0 approach managed to identify other 10
potential B cell epitopes (Table S3C). They all had <70%
identity to proteins present in humans. Nonetheless, a closer
inspection showed that the antigens of two of them were
predicted to localize at the mitochondrion and thus they were
discarded from further analysis. The remaining eight peptides
originated from four distinct antigens that were mostly predicted
to be secreted (Table 5). Moreover, there was experimental
evidence at the transcriptomics level indicating that they were




We ultimately provide the selection of epitopes that could
ensemble a potential epitope-based vaccine against T. cruzi that
fulfill the criteria of sequence conservation, widespread PPC, and
lack of identity to proteins present in humans (Table 6). The list
includes 18 CD8+ T cell epitopes from 17 distinct antigens, 2
CD4+ T cell epitopes from 2 antigens, and 10 B cell epitopes
from 6 antigens. In total, there are 30 epitopes from 25 antigens
of the parasite. All of them but one B cell epitope were predicted
(Table 6). The steps followed to arrive at these 30 epitopes are
depicted in Figure 2, which summarizes the work done and the
selection procedures performed toward the prioritization of the
CD8+ and CD4+ T cell epitopes (Figure 2A), as well as the B cell
epitopes (Figure 2B) finally included in the ensemble. Although
we have usedT. cruzi as our target organism, the strategy followed
could be employed to identify epitopes of interest toward the
design and further development of vaccine candidates against
other complex pathogens, for instance, Leishmania spp.
Such epitopes lists could be delivered as independent
or concatenated peptides (65), or as genetic constructs in
the form of “string-of-beads” (66). However, peptide-based
immunization has been deemed with poor immunogenicity
indexes (65). Therefore, a genetic immunization seems more
appealing, either in the form of plasmid DNA (pDNA) or
messenger RNA (mRNA). In this choice, pDNA-based delivery
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FIGURE 1 | Structure-predicted B cell epitope in T. cruzi KMP11 antigen. (A) Alignment of T. cruzi KMP11 sequence with the BepiPred2.0 prediction of the likelihood
of each residue of being part of an epitope (E). (B) PyMOL rendered picture of the T. cruzi KMP11 model with the predicted epitope QNKKFFADKPDESTL shown as
sticks and the KMP11 background featured as pale yellow ribbon. The N-term and C-term extremes of the protein are indicated.
still faces safety concerns, whereas recent advances in the
synthesis, manipulation, and immunization with mRNA have
made of it a very promising technology that can yield superior
immunogenicity than pDNA without the safety issues associated
to this (67). However, unlike pDNA, which is transcribed
inside a cell into a fully functional mRNA from only a coding
sequence, an mRNA has to be carefully designed to contain all
necessary elements. A schematic diagram of a potential mRNA-
based candidate construct is shown in Figure 3A. The mRNA
is usually obtained by in vitro transcription from a linearized
plasmid, which encodes all the structural elements of a functional
mRNA. In vitro mRNA structure has been described in detail
in the literature (67). Particularly, efficient translation requires
a functional 5′-cap structure that must be enzymatically added
after the transcription step. The natural 5′-cap is a 7-methyl-
guanosine linked to the mRNA by a 5′-5′ tri-phosphate bond,
but synthetic analogs called ARCAs (anti-reverse cap analogs)
have proven to result in superior translational efficiency and
are often currently used. As stability is a major concern with
mRNA molecules, several features may increase the stability
and/or translation rate of mRNA. Particularly, the incorporation
of 5′- and 3′-UTRs (untranslated regions) like those of β-globin
will help to increase the translation rate and stability of the
in vitro transcribed mRNA. In addition, the incorporation of a
Kozak sequence, which plays a major role in the initiation of
the translation, will also contribute to the mRNA stability and
translation efficiency. Finally, the in vitro transcribed mRNA
must contain a long polyadenosine monophosphate tail (polyA;
ideally 120–150 nucleotides long) that further regulates its
stability and translational efficiency. This polyA tail can be
either included in the template plasmid before transcription
or enzymatically added using recombinant poly(A)-polymerase
after transcription.
Besides, if epitopes are to be delivered as a genetic “string-
of-beads,” linker sequences will be required to space them,
precluding the formation of neo-epitopes that would distract
the desired immune response (69, 70). We used the tool
implemented by Schubert and Kohlbacher to optimally pre-
determine the sequence and length of those spacers for HLA
I-restricted epitopes (68) (Figure 3B). Taking into consideration
the relevance of a prominent CD8+ T cell response against the
parasite, we would place these epitopes first in the string as those
sequences located closer to the 5′-end of the construct would
be expressed at higher levels, thus inducing better immunogenic
responses (71) (Figure 3A).
We selected B cell epitopes paying attention to their
subcellular localization in the surface of the parasite and thus
they should be preceded by a surface secretory signal. Whether
this signal has to be placed at the 5′-end of all the epitopes or
just before the B cell epitopes chain will have to be determined.
Regarding CD4+ T cell epitopes, they will be functional as
far as they are physically linked to the others, so they could
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TABLE 5 | Selection of predicted T. cruzi-specific B cell epitopes.
Epitopes Antigen namea Antigen IDa Antigen subcellular
localizationb




QNKKFFADKPDESTL Kinetoplastid membrane protein
11 (KMP11)
XP_810488.1 – (1) AAH42613.1 (56.0%) EOQ36117.1 (62.5%) Y*/Y
EGESRHRTRSGSARHHR
RHHRNEAGG
Hypothetical protein, conserved XP_814578.1 −4 XP_006721247.1
(57.7)
EFX53962.1 (57.7) Y/Y






Associated kinase of Tb14-3-3,
putative
XP_819464.1 S (1) – XP_016882982.1 (24.1) Y/Y
GVCTSAEPRDLLDPVALCM
PYPGAERIIG
Associated kinase of Tb14-3-3,
putative
XP_819464.1 S (1) AAI12922.1 (44.8) EET82433.1 (37.9) Y/Y
NSQETPDQQKTGITRV Associated kinase of Tb14-3-3,
putative
XP_819464.1 S (1) AAY14773.1 (37.5) KZA05920.1 (68.8) Y/Y
REARGTSTPRRAETPSGG
SRVRGA
Associated kinase of Tb14-3-3,
putative
XP_819464.1 S (1) NP_573568.1 (37.5) OFQ81576.1 (54.2) Y/Y
KRSRSHNDGPARKRRR
KDNRP
Methyl-transferase, putative XP_803963 S (5) CAD38887.1 (61.9) EFD49634.1 (47.6) Y/N
NPSASPEASWQLNQSWNPL Hypothetical protein, conserved XP_809003.1 S (5) EAW82987.1 (52.6) EHS88047.1 (63.2) Y/N
aAntigen name and Accession reference obtained at NCBI database upon BLASTP analysis of the corresponding ORF_AA sequence as detailed in Materials and Methods. bAntigen
subcellular localization was predicted with TargetP1.1 (54); S, secreted; -, any other location; the number in parentheses stands for TargetP prediction “Reliability class” (RC), which
ranges from 1 to 5, where 1 indicates the strongest prediction. cPercentage of identity is given in parenthesis and stands for the number of identical residues per queried length of each
epitope to its corresponding blasted hit. dEvidence of expression in mammalian infective stages: existence (Y) or not (N) of evidence of expression by transcriptomics and/or proteomics
as described in TriTrypDB search by Gene ID (31); *the transcript expression value was higher in epimastigotes than in mammalian infective stages as described by Minning et al. (62).
be placed toward the 3′-end of the construct linked in “the
string-of-beads” (Figure 3A). The position, order, and spacing
of the B cell and CD4+ T cell epitopes will require a detailed
experimental evaluation. In an attempt to anticipate this task,
we included AAY linkers between B cell and CD4+ T cell
epitopes (69) and submitted the ensemble sequence to NetChop
proteasome processing predictor (56), as well as to VaxiJen v2
and RaptorX web portals to, respectively, obtain its antigenicity
score and 3D modeled structure (57, 58). NetChop predicted
that proteasome processing is shown in Figure 4. The calculated
antigenicity score of the ensemble was 0.68, indicating that the
construct was a probable antigen. In the retrieved 3D model,
the unstructured organization of the suggested spacers can be
observed, whereas the majority of the CD8+ T cell epitopes adopt
a β-sheet secondary conformation (Figure 5A). In contrast, the
two CD4+ T cell epitopes lead to the formation of an α-helix,
which localizes to the C-term (Figure 5A). With respect to the
B cell epitopes, the majority of those that could be modeled did
not adopt a defined secondary structure (Figure 5A). The 3D
configuration of half of them was not modeled by RaptorX as




RKRRRKDNRP. RaptorX also reported the solvent accessibility
(Acc) classification of each position in the ensemble (Figure 5B).
Remarkably, such Acc was described as maximum (exposed,
E) for 86.7% of the residues within B cell epitopes, which
would imply that they are accessible to B cell receptor/antibody
recognition (Figure 5B). It was medium-exposed (M) to E in
the case of CD4+ T cell epitopes (83.7%), and predominantly
a buried (B) Acc was calculated for CD8+ T cell nonamers
(63.0%) (Figure 5B).
DISCUSSION
Similarly to what has been suggested for leishmaniasis vaccines
(72), a vaccine for Chagas disease should fulfill the following
requirements: (i) it must be safe; (ii) it will have to induce long-
term protection against the wide diversity of T. cruzi strains; (iii)
such protection will need to be population broad and it should be
achieved with a minimum of immunizations; (iv) it will have to
be developed and produced very cost-effectively; and ideally (v)
it should be effective prophylactically and therapeutically.
The computational-assisted modular design of epitope-based
vaccines permits approaching some of those requirements
from the very start of the developmental process. In this
manuscript, we have applied several in silico methodologies
to the identification of epitopes of T. cruzi toward the design
of an epitope-based vaccine for Chagas disease (Figure 2).
Nonetheless, such strategy could likewise be explored for
the identification of epitope sequences of interest in other
complex pathogens responsible for chronic pathologies difficult
to intervene against, like Leishmania spp. In the case of
chronic persistent infections, regarding safety compliance, cross-
reactivity between the pathogen and the host is a feature that can
be explored in advance computationally. Such cross-reactivity
between T. cruzi and human antigens has been described and for
many years fueled the erroneous assumption that autoimmunity
was the sole cause of Chagas disease pathogenesis (73). Thus,
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TABLE 6 | Proposed epitope vaccine ensemble for T. cruzi.
Epitopes Antigen namea Antigen IDa Srcb
CD8+ T CELL EPITOPES VACCINE COMPONENT
VYGRFYYRF, RFFPSVFWR, FPFCWLPTY, MPAFQGWAF, KICHVVFFR,
RTYHMIWNR, RVFFWKVQR, MTFVFEARR, KMWQRTFTR,
RLWRWRCMR, RINFCFYVR, RQRAILMYR, KMRVWRHQR,
RMNLITWHR, FHDQTIFCL, MHDHYCFVL, IPMRRRRSL, FHFCITFCL
See Table 3 See Table 3 P
CD4+ T CELL EPITOPES VACCINE COMPONENT
DDELFHYFLWTFFFIDLLYAVM Hypothetical protein XP_816368.1 P
YIFIECFQIMRAFRLRGASFF Co-chaperone GrpE XP_804093.1 P
B CELL EPITOPES VACCINE COMPONENT
GTDEGLLLPVDNDGDESS Lipophosphoglycan biosynthetic protein/HSP90 superfamily XP_818651.1 E
QNKKFFADKPDESTL Kinetoplastid membrane protein 11 (KMP11) XP_810488.1 P
EGESRHRTRSGSARHHRRHHRNEAGG Hypothetical protein, conserved XP_814578.1 P
RRRRHSRSKRGEEDGGET Hypothetical protein, conserved XP_814578.1 P
GTPSRTTGRSTSTTRGVSRPTNGVTPSTSLAHRASTPGRTGTRSTTP
SRSSVLS
Associated kinase of Tb14-3-3, putative XP_819464.1 P
GVCTSAEPRDLLDPVALCMPYPGAERIIG Associated kinase of Tb14-3-3, putative XP_819464.1 P
NSQETPDQQKTGITRV Associated kinase of Tb14-3-3, putative XP_819464.1 P
REARGTSTPRRAETPSGGSRVRGA Associated kinase of Tb14-3-3, putative XP_819464.1 P
KRSRSHNDGPARKRRRKDNRP Methyl-transferase, putative XP_803963 P
NPSASPEASWQLNQSWNPL Hypothetical protein, conserved XP_809003.1 P
aAntigen name and ID reference obtained at NCBI database upon BLASTP analysis of the corresponding ORF_AA sequence as detailed in Materials and Methods. bSrc, source of the
epitopes: P, de novo predicted; E, experimentally validated retrieved from IEDB.
FIGURE 2 | Flowchart summary of the epitope identification and prioritization steps followed in our strategy. (A) depicts the steps followed to arrive at the selected
CD8+ and CD4+ T cell epitopes included in the ensemble proposed, whereas (B) shows the strategies undertaken to select the B cell epitopes finally included. The
larger boxes show the steps; triangles show IEDB-derived T. cruzi-specific unique epitopes, and the hexagons contain the finally selected epitopes. This figure was
made at https://www.lucidchart.com.
the epitope sequences we have prioritized into the ensemble are
<70% identity to any protein present in humans, including those
of the human microbiome. Nonetheless, we should be cautious
with respect to the occurrence of cross-reactivity. Currently
available data indicate that occasionally a single mutation can
disrupt the antigen recognition process (74), whereas it is possible
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FIGURE 3 | Schematic diagram of an mRNA vaccine construct. (A) Schematic diagram of a candidate mRNA construct. (B) Optimal organization and ordering of
CD8+ T cell epitopes part of the vaccine, as well as optimal linker sequences as determined with OptiVac tool (68).
FIGURE 4 | NetChop predictions of proteasome processing in the full peptide sequence of the vaccine ensemble. S, spacers; P, NetChop predictions.
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FIGURE 5 | RaptorX modeling and accessibility calculations of the epitope-containing ensemble. (A) 3D model of the ensemble, respectively, encompassing from
N-term to C-term the listed CD8+ T cell epitopes (blue), B cell epitopes* (orange), and CD4+ T cell epitopes (red). Linkers are shown in gray. *, B cell epitopes
QNKKFFADKPDESTL, EGESRHRTRSGSARHHRRHHRNEAGG, RRRRHSRSKRGEEDGGET,
GTPSRTTGRSTSTTRGVSRPTNGVTPSTSLAHRASTPGRTGTRSTTPSRSSVLS, and KRSRSHNDGPARKRRRKDNRP were not modeled by RaptorX as they were
considered disordered. (B) Full peptide sequence of the vaccine ensemble (Ens) aligned with RaptorX-provided solvent accessibility (Acc) per position. CD8+ T cell
epitopes are shaded light blue; B cell epitopes are highlighted in yellow; and CD4+ T cell epitopes are in red. B, buried; M, medium (light gray); E, exposed (gray).
that cross-recognition may occur even with low similarity levels
(75). The structural mechanisms of epitope recognition, which
could largely contribute to better understand these features, are
yet under debate. Overall, it is common to think that the lower the
identity, the better it will be toward avoiding any potential cross-
reactivity. However, there is not a study specifically addressing
what percentage of similarity removes the chance for such cross-
reactivity in the context of epitopes vs. self-peptide recognition
(76). Notwithstanding, if we look at the epitope cross-reactivity
phenomenon as a matter of ligand–receptor complementarity,
this is comparable to the self-complementarity process within
folded proteins. There, a 70% threshold value is used for
protein sequence analysis (77). Such cutoff has been described
as conservative by an approach aimed at reducing epitope
redundancy, particularly in relation to long epitopes such as
CD4+ T cell and B cell epitopes (78). Regarding nonameric CD8+
T cell epitopes, it has been described that residue positions 2
and 9 are key to determine epitope binding to MHC-I, whereas
residues 3–6 and 8 are engaged in T cell receptor (TCR) motif
recognition (79). Thereby, we think that establishing a<70% cut-
off, we are restricting the selection of any T. cruzi epitopes that
are identical to peptides present in humans in more than six (out
of nine) residues. Then, at least one of those key positions will
always be different in any of the CD8+ T cell epitopes progressed
by us to any peptide sequence of that length present in humans.
Nonetheless, as it is mentioned above, cross-recognition may still
occur with low similarity, so any potential cross-reactivity will
have to be carefully addressed.We expect that this could be better
anticipated by computational tools in the near future as structural
comprehension of the epitope recognition process advances. The
rationale of applying this criterion of selecting non-identical
sequences to proteins in the host susceptible to vaccination has
another advantage, as it lines up with the hypothesis that any
peptide sequence that is non-conserved in the host will likely be
more immunogenic, which is certainly a desirable attribute of any
vaccine. Indeed, a lower ability to induce an immune response
has been described for peptides from commensal bacteria of the
human microbiome (80).
In the aspiration of inducing protection against T. cruzi
diverse strains, we did select epitopes that besides being <70%
identical to human proteins were pan-conserved to a certain
threshold among the parasite strains available at TriTrypDB
release 35. The idea is that a single vaccine would cover
the parasite’s ample phylogenetic and geographic space. The
importance of selecting invariant protein regions also brings the
concept that evolutionary conserved sequences likely represent
biologically relevant moieties of the parasite genome and are
therefore good targets for therapeutic intervention as it has
been described in viral, bacterial, and other parasitic diseases
(25–28, 81). Besides, we prioritized T cell epitopes accordingly
to their calculated PPC in the target population, i.e., Latin
American population, so as to predict a maximum coverage.
Therefore, thanks to the use of computational tools and
immunoinformatics, we can fence in the parasite’s genetic
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diversity and anticipate to some extent the vaccine coverage from
a standpoint as early as the selection of the antigens/epitopes that
will go in it.
Another key feature, especially in the development of
therapeutics for NTDs, is certainly cost-effectiveness. In fact,
considering an average Chagas disease prevalence of ∼1% in
Latin America (82), keeping developmental costs as low as
possible will be fundamental (83). In this respect, a computer-
guided selection of the antigens/epitopes can definitely aid to
save costs as it narrows down the number of them that will have
to be evaluated experimentally. In addition, in an epitope-based
strategy with multiple epitopes from multiple antigens, epitopes
will have to be delivered either as peptides or genetic constructs,
which are cheaper to produce than recombinant proteins or
vectors. Nevertheless, vaccine efficacy will be fundamental to
determine its final cost-effectiveness (83), and this is something
that remains to be determined experimentally.
Vaccine efficacy is connected to the level of immunogenicity
and the induction of long-term (memory) protection. Thus,
thinking about the preferred delivery system, an RNA-
based strategy might be the most suitable. It would ensure
direct cytoplasm processing of the epitopes supporting higher
expression efficiencies and stronger immune responses in
comparison to protein subunit immunizations or pDNA usage
(67). In fact, mRNA vaccine candidates against several infectious
diseases like flu, rabies, HIV-1, or Zika virus infection have
worked very well in preclinical models and reached clinical
testing (67). They all rely on the delivery of complete viral
antigens, whereas a parasitic vaccine will require the delivery
of multiple antigens that would face size constrains. Here, an
epitope-based vaccine encompassing a fine selection of the most
desirable peptides can overcome this phenomenon. The RNA-
based delivery of epitopes has been clinically evaluated already
in search of novel immunotherapies for advanced melanoma
patients (84). Although it may be a limitation, in principle,
no adjuvant should be inoculated with the vaccine as the
RNA backbone is known to have self-adjuvant properties (67).
Although not including an adjuvant would be desirable for a
Chagas disease vaccine as it would contribute to save costs,
whether an adjuvant will be required or not will need to be
determined experimentally.
Despite the fact that the computer-guided design of vaccines
offers a series of advantages, a caveat of our approach is that
only linear peptide epitopes can be computed, which excludes
conformational and glycan epitopes from the ensemble. The
outcome of the two-sided strategy that consisted in crossing
experimentally described unique T. cruzi epitopes (from IEDB)
with the invariant parasite proteome (“IEDB × INVARIANT
PROTEOME”) barely yielded a single B cell epitope (Table 2).
We had hoped to recover more sequences, but this result was not
surprising at all given the limited number of T. cruzi antigens
studied. Unique T. cruzi T cell epitopes from positive assays
at IEDB originated from 45 distinct antigens (Tables S3A,B),
whereas the 2000 unique B cell epitopes retrieved originated from
a total of 133 distinct antigens (Table S3C), meaning that the
majority of the parasite protein space is yet unexplored. As a
result, we were obliged to a de novo prediction of epitopes. In
truth, we applied highly restrictive thresholds and only used the
very top ranked predicted sequences, but the first thing to do next
will be to validate them experimentally.
The antigens of origin of over half of the epitopes selected
appeared annotated as hypothetical proteins, which further
conveys the need to increase the knowledge about the parasite
protein space. These proteins will have to be further studied and
annotated, but the fact that their sequences are highly conserved
among T. cruzi genomes seems to suggest that they are meant
to play an important role in the parasite’s biology. Among those
antigens that had functional annotation, it is worth to highlight
KMP11, which has been previously described to be immunogenic
and protective (63, 85). The rest were mostly putative enzymes
with likely intracellular sub-localization, a feature not surprising
given the conservancy criteria used to select the epitopes. In
addition, the majority of the selected epitopes were from proteins
that had evidences of expression specific to the mammalian
infective stages of the parasite (see Tables 2–5). Nonetheless, we
found that a few of them were described to be slightly higher
expressed [by transcriptomic microarray with the Brazil strain;
(62)] in epimastigotes than in the rest of the stages (see Tables 3–
5). Since one of such antigens was KMP11 (Table 5), which has
been thoroughly studied and known to be the origin of several
immunogenic epitopes, we decided to keep those epitopes in.
In comparison to other genome screening of T. cruzi epitopes
for vaccine design (86), the epitopes included in this ensemble
are human epitopes or predicted in the human immunological
context. That is, they either were predicted to bind to human
MHC class I or class II molecules or have been validated with
clinical samples in the case their origin is at IEDB (only B
cell epitope GTDEGLLLPVDNDGDESS). This will likely be
advantageous for a rapid progression of the candidate, but it
entails that at the preclinical developmental stage, the ensemble
will require to be tested in humanized mice, for instance, the
transgenic strains already available (87–89).
In an epitope-based vaccination strategy with multiple
epitopes from multiple antigens, each of those epitopes
represents an independent immunological entity. In the case
of a Chagas disease vaccine, the ensemble must include CD8+
and CD4+ T cell epitopes as well as B cell epitopes (8–11), and
thus their positioning and ordering within the construct will
have to be carefully studied. We have used the tool developed
by Schubert and Kohlbacher for the design of the “string-of-
beads” fraction with CD8+ T cells epitopes (68, 70), which take
into account not only the optimum order of the epitopes, but
also the type and length of the linker sequences separating each
pair of them. The relevance of adequately choosing the spacers
resides in that they can be immunogenic themselves or give rise
to novel epitopes which would preclude or downsize the desired
immune response. Following the work by Velders et al. (69), we
have included AAY linkers between B and CD4+ T cell epitopes,
and they were adequately predicted by NetChop in the ensemble
proposed (Figure 4). Nonetheless, epitopes’ ultimate ordering
and localization as well as that of any spacers in between will have
to be empirically determined. Similarly, taking into account that
the immunogenicity of isolated epitopes could change when they
are put together in a string of beads array, although VaxiJen v2
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score for both constructs was above the threshold, their overall
immunogenicity will have to be carefully studied experimentally.
Ideally, the availability of a Chagas disease vaccine would
substitute BNZ and NFX treatments. However, the co-
administration of vaccine and drug is also being investigated
as the former could contribute to reduce the drug’s dosage,
and thus its related toxicity, while maintaining its efficacy as
described recently (90). In any case, vaccination is arguably
the most successful biomedical intervention ever developed
against infectious diseases (91), and reverse vaccinology was
shown to be fundamental toward the successful development
of a multi-antigen vaccine against the otherwise difficult-to-
tackle pathogen meningococcus serogroup B (92). Multi-antigen
vaccines might also be the answer to obtain immunotherapeutic
products against other biologically complex pathogens such as
the parasites responsible for many of the currently recognized
NTDs, whose treatment still relies on toxic chemotherapies (93).
The advent of next-generation sequencing has allowed access to
genomics information of several of these pathogens, like T. cruzi.
For many of them, the availability of vaccines would mean a
major breakthrough in their clinical management and therefore
stronger efforts made in this direction would surely pay back.
CONCLUSIONS AND LIMITATIONS
Chagas disease, a neglected infectious disease caused by the
parasite T. cruzi, exerts a huge burden in Latin America. In
recent decades, its impact has been globalized mainly to North
American countries and Europe. Upon a generally asymptomatic
acute stage, the infection becomes persistent and it is in its
chronic stage when the disruption of heart and/or gut tissues
occurs. The damage to these tissues can be fatal if untreated
and up to 30% of those chronically infected are estimated to
end up developing these symptoms. Despite BNZ and NFX
being available to treat the infection, their efficacy is reduced
at the chronic stage and both have frequent adverse effects
associated. In this context, the availability of a vaccine that could
prevent the infection or the development of the symptomatology
would be a major breakthrough for the clinical control of the
disease. Several efforts have been initiated in this respect, but the
biological complexity of the parasite and the lack of funding to
progress any candidate beyond preclinical testing have hindered
the matter. We herein propose an alternative vaccine approach
based on epitopes from a range of different parasite antigens to
cope with the parasite’s antigenic complexity. The epitopes were
prioritized considering their conservation among the distinct
T. cruzi sequenced genomes so as to provide a single pan-
vaccine, which would contribute to save developmental costs.
Besides, the proposed epitope-based vaccine candidate would
be delivered in the form of a genetic construct that can be
synthetized at a fraction of the cost of producing recombinant
protein subunits or virus vectored antigens. The provided
ensemble would elicit both cellular and humoral immunity,
required to control the intracellular and extracellular forms of
the parasite (amastigotes and trypomastigotes, respectively) in
the mammalian host. The T cell component consists of 18 CD8+
T cell epitopes from 17 distinct antigens and 2 CD4+ T cell
epitopes from another 2 antigens that could elicit a cellular
response in virtually the whole target population of such a
vaccine. On the other hand, the B cell component of the vaccine
encompasses a total of 10 epitopes from six different surface-
exposed antigens that could elicit antibodies against the free
swimming trypomastigote stage. Notably, all the epitopes in
the ensemble were prioritized in agreement with their lack of
identity to any protein sequences present in humans in order to
preclude cross-reactivity reactions thus favoring the safety of the
vaccine candidate.
We initially attempted to identify conserved epitopes
that had been experimentally validated and deposited in
the IEDB database, but it happened that only one of the
T. cruzi-specific unique epitopes at IEDB (B cell epitope
GTDEGLLLPVDNDGDESS) could be rescued out of the
conserved T. cruzi proteome generated. Therefore, we had to
perform de novo predictions of epitopes departing from that
conserved proteome. Aware of the limitations of this procedure,
we were very stringent and only selected top qualifying predicted
epitopes. Nonetheless, whether they are processed and presented
in the course of an infection by T. cruzi remains to be
demonstrated. Even if immunogenic, we would still not know to
what extent the here presented vaccine ensemble could provide
protection from T. cruzi infection. This is something that we will
have to evaluate in forthcoming experiments upon validation of
the epitopes.
In relation to the T cell component, we assumed population
coverage estimates based on peptide binding predictions to
MHC molecules. Although the reliability of peptide–MHC
binding predictions has been widely proved, this is a feature
that will need further testing. An appropriate processing of
the antigens is a key feature toward the immunogenicity of
the epitopes, and this will have to be thoroughly studied in
relation to the delivery of the epitopes in the form of a genetic
construct. We have used a computational tool to provide the
optimum ordering and spacing of the CD8+ T cell epitope
component in the suggested construct. Nonetheless, this will
require further proof as well as it will be necessary to evaluate
which is the optimum order and spacing to achieve maximum
immunogenicity with the CD4+ T cell and B cell epitopes.
In relation to the latter, we do not provide any glycan-based
epitopes as they cannot be extracted with the protein-based
reverse vaccinology procedure followed. We neither include any
conformational epitopes since these cannot be isolated from
their context and we only focused on linear epitopes. It needs
to be tested whether these epitopes elicit antibodies that are
capable of recognizing the native protein conformations. Omics-
data repositories such as EuPathDB and IEDB (94, 95), along
with the series of immunoinformatics tools described in this
work, are extremely useful to perform in silico studies that
can help to guide wet lab experiments contributing to save
time and money. Nonetheless, the next step will be to take
these epitopes onto in vitro immunological assays to validate
them and determine their immunogenicity and then devise
challenge-protection preclinical studies to ultimately qualify
the strategy.
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